Design and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 study
<p><strong>Data System.</strong> The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England.</p> <p><strong>Da...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Public Health Association
2023
|
| _version_ | 1797113020965453824 |
|---|---|
| author | Ward, H Atchison, C Whitaker, M Davies, B Ashby, D Darzi, A Chadeau-Hyam, M Riley, S Donnelly, CA Barclay, W Cooke, GS Elliott, P |
| author_facet | Ward, H Atchison, C Whitaker, M Davies, B Ashby, D Darzi, A Chadeau-Hyam, M Riley, S Donnelly, CA Barclay, W Cooke, GS Elliott, P |
| author_sort | Ward, H |
| collection | OXFORD |
| description | <p><strong>Data System.</strong> The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England.</p>
<p><strong>Data Collection/Processing.</strong> We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020–May 2021).</p>
<p><strong>Data Analysis/Dissemination.</strong> We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications.</p>
<p><strong>Public Health Implications.</strong> REACT-2 estimated the scale and variation in antibody prevalence over time. Community self-testing and -reporting produced rapid insights into the changing course of the pandemic and the impact of vaccine rollout, with implications for future surveillance.</p> |
| first_indexed | 2024-03-07T08:00:23Z |
| format | Journal article |
| id | oxford-uuid:62642301-55a9-4bee-95ca-3c3584e3e6b3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-04-09T03:57:49Z |
| publishDate | 2023 |
| publisher | American Public Health Association |
| record_format | dspace |
| spelling | oxford-uuid:62642301-55a9-4bee-95ca-3c3584e3e6b32024-03-26T11:07:24ZDesign and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:62642301-55a9-4bee-95ca-3c3584e3e6b3EnglishSymplectic ElementsAmerican Public Health Association2023Ward, HAtchison, CWhitaker, MDavies, BAshby, DDarzi, AChadeau-Hyam, MRiley, SDonnelly, CABarclay, WCooke, GSElliott, P<p><strong>Data System.</strong> The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England.</p> <p><strong>Data Collection/Processing.</strong> We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020–May 2021).</p> <p><strong>Data Analysis/Dissemination.</strong> We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications.</p> <p><strong>Public Health Implications.</strong> REACT-2 estimated the scale and variation in antibody prevalence over time. Community self-testing and -reporting produced rapid insights into the changing course of the pandemic and the impact of vaccine rollout, with implications for future surveillance.</p> |
| spellingShingle | Ward, H Atchison, C Whitaker, M Davies, B Ashby, D Darzi, A Chadeau-Hyam, M Riley, S Donnelly, CA Barclay, W Cooke, GS Elliott, P Design and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 study |
| title | Design and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 study |
| title_full | Design and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 study |
| title_fullStr | Design and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 study |
| title_full_unstemmed | Design and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 study |
| title_short | Design and implementation of a national program to monitor the prevalence of SARS-CoV-2 IgG antibodies in England using self-testing: the REACT-2 study |
| title_sort | design and implementation of a national program to monitor the prevalence of sars cov 2 igg antibodies in england using self testing the react 2 study |
| work_keys_str_mv | AT wardh designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT atchisonc designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT whitakerm designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT daviesb designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT ashbyd designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT darzia designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT chadeauhyamm designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT rileys designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT donnellyca designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT barclayw designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT cookegs designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study AT elliottp designandimplementationofanationalprogramtomonitortheprevalenceofsarscov2iggantibodiesinenglandusingselftestingthereact2study |